Helen Oladapo, PhD
Lecturer
Education
- Ph.D. in Integrated Biosciences (Conc. Pharmacology), North Carolina Central University, Durham, NC, 2017
- M.S. in Pharmaceutical Sciences, North Carolina Central University, Durham, NC, 2012
- B.S. in Biology, East Carolina Central University, Greensville, NC, 2007
Professional Experience
- Lecturer, Department of Biology, Baylor University, Waco, TX, 2021–Present
- Adjunct Professor, Department of Biology, LONE STAR COLLEGE NORTH HARRIS, Houston, TX, 2019–2021
- Clinical Research Internship, NORTH TEXAS CLINICAL TRIALS, Fort Worth, TX, 2018
- Postdoctoral Research Fellow, Department of Pharmaceutical Sciences, The Biomanufacturing Research Institute and Technology Enterprise (BRITE), NORTH CAROLINA CENTRAL UNIVERSITY, Durham, NC, 2017
Major areas of research
- Pharmacology and Drug Discovery
- Cancer and Molecular Biology
Course Taught
- BIO 1305 Modern Concepts of Bioscience I
- BIO 1306 Modern Concepts of Bioscience II
- BIO 3342 Cell and Molecular Biology
Publications
- Olayinka Abudu, Gold Lawal, Ifeoluwa Adewuyi, Helen Oladapo, Olufolahan Oduyemi. Drivers of Circular Food Economies in Mississippi, USA. Journal of Economics and Sustainable Development. Nov. 2022. ISSN 2222-1700 (Paper) ISSN 2222-2855 (Online). Vol.13, No.22, 2022
- Olayinka Abudu, Gold Lawal, Ifeoluwa Adewuyi, Helen Oladapo, Olufolahan Oduyemi. Barriers to Transitioning to a Circular Food Economy in Mississippi, USA. Journal of Economics and Sustainable Development. Dec. 2022. Vol 13, No 24 (2022)
- Michael Tarpley, Helen Oladapo, Thomas B Caligan, Rob U Onyenwoke, Kevin P Williams. Data supporting a pilot high-throughput screen of a drug library for identification of DYRK1A inhibitors and high-content imaging analysis of identified harmine analogs. Science Direct. 2021
- Tarpley M., Oladapo H.O., Strepay D., Caligan T.B., Chdid L., Shehata H., Roques J.R., Onyenwoke R.U., Darr D.B., Williams K.P. Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies. Eur. J. Pharm. Sci. 2021;162
- Helen O. Oladapo, Michael Tarpley, Scott J. Sauer, Kezia A. Addo, Shalonda M. Ingram, Dillon Strepay, Ben K. Ehe, Lhoucine Chdid, Michael Trinkler, Jose R. Roques, David B. Darr, Jodie M. Flemingc, Gayathri R. Devib f, Kevin P. Williams. Pharmacological targeting of GLI1 inhibits
- proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells. Cancer Lett, 2017. 411: p. 136-149